natgillin/translations-raw huggingface dataset:
Aripiprazole Accord 5 mg tablets are blue colored, approximately 8.1 mm in length, 4.6 mm in width, modified rectangle shaped, biconvex, uncoated tablets, debossed with “A5” on one side and another side is plain.
Aripiprazol Accord 5 mg tablete su plave, bikonveksne neobložene tablete modificiranog pravokutnog oblika duge oko 8,1 mm i široke oko 4,6 mm s utisnutom oznakom „A5“ na jednoj strani i bez oznake na drugoj strani.
Aripiprazole Accord 5 mg tablets aripiprazole
Aripiprazol Accord 5 mg tablete aripiprazol
Aripiprazole Accord 5 mg tablets Aripiprazole Accord 10 mg tablets Aripiprazole Accord 15 mg tablets Aripiprazole Accord 30 mg tablets
Aripiprazol Accord 5 mg tablete Aripiprazol Accord 10 mg tablete Aripiprazol Accord 15 mg tablete Aripiprazol Accord 30 mg tablete
Aripiprazole Accord 5 mg tablets Aripiprazole Accord 10 mg tablets Aripiprazole Accord 15 mg tablets Aripiprazole Accord 30 mg tablets aripiprazole
Aripiprazol Accord 5 mg tablete Aripiprazol Accord 10 mg tablete Aripiprazol Accord 15 mg tablete Aripiprazol Accord 30 mg tablete aripiprazol
Aripiprazole Accord 5/10/15 mg tablets are also available in HDPE bottle with PPCRC closure containing 30 or 100 tablets.
Aripiprazol Accord 5/10/15 mg tablete također su dostupne u HDPE boci s PPCRC čepom koja sadrži 30 ili 100 tableta.
Aripiprazole Accord contains lactose
Aripiprazol Accord sadrži laktozu
Aripiprazole Accord contains lactose.
Aripiprazol Accord sadrži laktozu.
Aripiprazole Accord contains the active substance aripiprazole and belongs to a group of medicines called antipsychotics.
Aripiprazol Accord sadrži djelatnu tvar aripiprazol i pripada skupini lijekova koji se zovu antipsihotici.
Aripiprazole Accord contains the active substance aripiprazole and is a ‘generic medicine’.
Aripiprazole Accord sadrži djelatnu tvar aripiprazol i predstavlja „generički lijek”.
Aripiprazole Accord is effective in a dose range of 10 to 30 mg/day.
Aripriprazole Accord je učinkovit u rasponu doza od 10 do 30 mg/dan.
Aripiprazole Accord is for oral use.
Aripiprazol Accord je namijenjen za peroralnu primjenu.
Aripiprazole Accord is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment (see section 5.1).
Aripiprazol Accord je indiciran za liječenje umjerenih do teških maničnih epizoda u bipolarnom poremećaju tipa I te za prevenciju nove manične epizode u odraslih osoba s pretežno maničnim epizodama u kojih su prethodne manične epizode odgovorile na liječenje aripiprazolom (vidjeti dio 5.1).
Aripiprazole Accord is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.
Aripiprazol Accord je indiciran za liječenje shizofrenije u odraslih i adolescenata u dobi od 15 i više godina.
Aripiprazole Accord is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older (see section 5.1).
Aripiprazol Accord je indiciran za liječenje umjerenih do teških maničnih epizoda u bipolarnom poremećaju tipa I u adolescenata u dobi od 13 godina i starijih tijekom najdulje 12 tjedana (vidjeti dio 5.1).
Aripiprazole Accord is not recommended for use in patients with schizophrenia below 15 years of age due to insufficient data on safety and efficacy (see sections 4.8 and 5.1).
Aripiprazol Accord se ne preporučuje za primjenu u bolesnika sa shizofrenijom mlađih od 15 godina, zbog nedostatnih podataka o sigurnosti i djelotvornosti (vidjeti dijelove 4.8 i 5.1).
Aripiprazole Accord is used in patients aged 15 years or over; bipolar I disorder, a mental illness in which patients have manic episodes (periods of abnormally high mood), alternating with periods of normal mood.
Aripiprazole Accord koristi se u bolesnika u dobi od 15 godina ili starijih; kod bipolarnog poremećaja tipa I, mentalne bolesti u slučaju koje bolesnici imaju manične epizode (razdoblja abnormalno visokog raspoloženja), koje se izmjenjuju s razdobljima normalnog raspoloženja.
Aripiprazole and other antipsychotic active substances should be used cautiously in patients at risk for aspiration pneumonia.
Aripiprazol i druge djelatne tvari antipsihotika moraju se koristiti s oprezom u bolesnika s rizikom za aspiracijsku upalu pluća.
Aripiprazole can have minor or moderate influence on the ability to drive and use machines due to potential nervous system and visual effects, such as sedation, somnolence, syncope, vision blurred, diplopia (see section 4.8).
Aripiprazol može malo do umjereno utjecati na sposobnost upravljanja vozilima i rada sa strojevima zbog mogućih učinaka na živčani i vidni sustav, kao što su sedacija, somnolencija, sinkopa, zamagljen vid, diplopija (vidjeti dio 4.8).
Aripiprazole dose should be doubled when concomitant administration of aripiprazole occurs with carbamazepine.
Doza aripiprazola mora se udvostručiti kad se uz aripiprazolistodobno primjenjuje karbamazepin.
Aripiprazole doses ranging from 0.5 to 30 mg administered once a day to healthy subjects for 2 weeks produced a dose-dependent reduction in the binding of 11C-raclopride, a D2/D3 receptor ligand, to the caudate and putamen detected by positron emission tomography.
Doze aripiprazola u rasponu od 0,5 do 30 mg primijenjene jedanput dnevno u zdravih ispitanika tijekom 2 tjedna proizvele su o dozi ovisno smanjenje vezivanja 11C-rakloprida, liganda D2/D3 receptora, u nukleus caudatusu i putamenu, kako se pokazalo pozitronskom emisijskom tomografijom.
Aripiprazole exhibited high binding affinity in vitro for dopamine D2 and D3, serotonin 5HT1a and 5HT2a receptors and moderate affinity for dopamine D4, serotonin 5HT2c and 5HT7, alpha-1 adrenergic and histamine H1 receptors.
Aripiprazol je in vitro pokazao visok afinitet vezanja za dopaminske D2 i D3, serotoninske 5HT1a i 5HT2a receptore i umjeren afinitet za dopaminske D4, serotoninske 5HT2c i 5HT7, alfa-1 adrenergičke i histaminske H1 receptore.
Aripiprazole exhibits high binding affinity in vitro for dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A receptors and has moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha-1 adrenergic, and histamine H1 receptors.
Aripiprazol pokazuje visok afinitet vezanja in vitro za dopaminske D2 i D3 i serotoninske 5-HT1A i 5-HT2A receptore i ima umjereni afinitet prema dopaminskim D4, serotoninskim 5-HT2C i 5-HT7, alfa-1 adrenergičkim i histaminskim H1 receptorima.
Aripiprazole is effective in a dose range of 10 to 30 mg/day.
Aripiprazole Mylan Pharma je učinkovit u rasponu doza od 10 do 30 mg/dan.
Aripiprazole is metabolised by multiple pathways involving the CYP2D6 and CYP3A4 enzymes, but not CYP1A enzymes.
Aripiprazol se metabolizira većim brojem puteva koji uključuju enzime CYP2D6 i CYP3A4, ali ne i enzime CYP1A.
Aripiprazole is not indicated for the treatment of dementia-related psychosis.
Aripiprazol nije indiciran za liječenje psihoze povezane s demencijom.
Aripiprazole is not indicated for the treatment of dementia-related psychosis.
Aripiprazol Sandoz nije indiciran za liječenje psihoze povezane s demencijom.
Aripiprazole is not indicated for the treatment of dementia-related psychosis.
Aripiprazolnije indiciran za liječenje psihoze povezane s demencijom.
Aripiprazole is thought to act mainly by being a ‘partial agonist’ at the receptors for the neurotransmitters dopamine and 5-hydroxytryptamine (also called serotonin).
Smatra se da aripiprazol djeluje uglavnom kao „parcijalni agonist” za receptore neurotransmitera dopamina i 5-hidroksitriptamina (također zvani serotonin).
Aripiprazole is thought to act mainly by being a ‘partial agonist’ for the receptors for the neurotransmitters dopamine and 5- hydroxytryptamine (also called serotonin).
Smatra se da aripiprazol djeluje uglavnom kao „parcijalni agonist” za receptore neurotransmitera dopamina i 5- hidroksitriptamina (također zvani serotonin).
Aripiprazole is thought to act mainly by being a ‘partial agonist’ for the receptors for the neurotransmitters dopamine and 5- hydroxytryptamine (also called serotonin).
Smatra se da aripiprazol djeluje uglavnom kao „parcijalni agonist” za receptore neurotransmitera dopamina i 5-hidroksitriptamina (također zvani serotonin).
Aripiprazole is thought to act mainly by being a ‘partial agonist’ for the receptors for the neurotransmitters dopamine and 5-hydroxytryptamine (also called serotonin).
Smatra se da aripiprazol djeluje uglavnom kao „parcijalni agonist” za receptore neurotransmitera dopamina i 5-hidroksitriptamina (također zvani serotonin).
Aripiprazole Mylan Pharma 10 mg tablets
Aripiprazole Mylan Pharma 10 mg tablete
Aripiprazole Mylan Pharma 10 mg tablets
Aripiprazole Mylan Pharma 10 mg tablete EU/1/15/1005/004
Aripiprazole Mylan Pharma 10 mg tablets are pink, round and biconvex of 8.1mm in diameter, engraved with ‘10’ on one side.
Aripiprazola Mylan Pharma 10 mg tablete Su ružičaste, okrugle sam bikonvenksnim od 8.1mm promjera, s ugraviranim '10' na jednoj strain.
Aripiprazole Mylan Pharma 10 mg tablets aripiprazole
Aripiprazole Mylan Pharma 10 mg tablete aripiprazol
Aripiprazole Mylan Pharma 15 mg tablets
Aripiprazole Mylan Pharma 15 mg tablete
Aripiprazole Mylan Pharma 15 mg tablets
Aripiprazole Mylan Pharma 15 mg tablete EU/1/15/1005/007
Aripiprazole Mylan Pharma 15 mg tablets are yellow, round and biconvex of 10.1mm in diameter, engraved with ‘15’ on one side.
Aripiprazol Mylan Pharma 15 mg tablete su žute, okrugle i bikonvenksnim od 10.1mm u promjeru, s ugraviranim "15" na jednoj strani.
Aripiprazole Mylan Pharma 15 mg tablets aripiprazole
Aripiprazole Mylan Pharma 15 mg tablete aripiprazol
Aripiprazole Mylan Pharma 30 mg tablets
Aripiprazole Mylan Pharma 30 mg tablete EU/1/15/1005/010
Aripiprazole Mylan Pharma 30 mg tablets aripiprazole
Aripiprazole Mylan Pharma 30 mg tablete aripiprazol
Aripiprazole Mylan Pharma 5 mg tablets
Aripiprazole Mylan Pharma 5 mg tablete EU/1/15/1005/001
Aripiprazole Mylan Pharma 5 mg tablets aripiprazole
Aripiprazole Mylan Pharma 5 mg tablete aripiprazol
Aripiprazole Mylan Pharma 5 mg tablets Aripiprazole Mylan Pharma 10 mg tablets Aripiprazole Mylan Pharma 15 mg tablets Aripiprazole Mylan Pharma 30 mg tablets
Aripiprazole Mylan Pharma 5 mg tablete Aripiprazole Mylan Pharma 10 mg tablete Aripiprazole Mylan Pharma 15 mg tablete Aripiprazole Mylan Pharma 30 mg tablete
Aripiprazole Mylan Pharma 5 mg tablets Each tablet contains 5 mg of aripiprazole.
Aripiprazole Mylan Pharma 5 mg tablete
Aripiprazole Mylan Pharma contains the active substance aripiprazole and is a ‘generic medicine’.
Aripiprazole Mylan Pharma sadrži djelatnu tvar aripiprazol i "generički je lijek".
Aripiprazole Mylan Pharma is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment (see section 5.1).
Aripiprazole Mylan Pharma je indiciran za liječenje umjerenih do teških maničnih epizoda u bipolarnom poremećaju tipa I te za prevenciju nove manične epizode u odraslih osoba s pretežno maničnim epizodama u kojih su prethodne manične epizode odgovorile na liječenje aripiprazolom (vidjeti dio 5.1).
Aripiprazole Mylan Pharma is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older (see section 5.1).
Aripiprazole Mylan Pharma je indiciran za liječenje umjerenih do teških maničnih epizoda u bipolarnom poremećaju tipa I u adolescenata u dobi od 13 godina i starijih tijekom najdulje 12 tjedana (vidjeti dio 5.1).
Aripiprazole Mylan Pharma is used in patients aged 15 years or over; bipolar I disorder, a mental illness in which patients have manic episodes (periods of abnormally high mood), alternating with periods of normal mood.
Aripiprazole Mylan Pharma se koristi u bolesnika u dobi od 15 godina ili starijih; bipolarnom poremećaju tipa I, mentalnom bolesti u slučaju koje bolesnici imaju manične epizode (razdoblja abnormalno visokog raspoloženja), koje se izmjenjuju s razdobljima normalnog raspoloženja.
Aripiprazole Mylan Pharma tablets are used to treat adults and adolescents aged 13 years and older who suffer from a condition with symptoms such as feeling "high", having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability.
Aripiprazole Mylan Pharma tablete se koriste za liječenje odraslih osoba te adolescenata u dobi od 13 godina i starijih koji boluju od stanja čiji su simptomi “povišeno” raspoloženje, pretjerana količina energije, potreba za manjom količinom sna nego obično, vrlo brz govor i ubrzan tijek misli te ponekad teška razdražljivost.
Aripiprazole Mylan Pharma tablets contain maltose
Aripiprazole Mylan Pharma tablete sadrže maltoza
Aripiprazole Mylan Pharma tablets contain maltose.
Aripiprazol Mylan Pharma tablete sadrže maltozu.
Aripiprazole Mylan Pharma tablets contain the active substance aripiprazole and belong to a group of medicines called antipsychotics.
Aripiprazole Mylan Pharma tablete sadrži djelatnu tvar aripiprazol i pripadaju skupini lijekova koji se zovu antipsihotici.
Aripiprazole Mylan Pharma1 aripiprazole
Aripiprazole Mylan Pharma1 aripiprazol
Aripiprazole Sandoz 10 mg
Aripiprazol Sandoz 10 mg
Aripiprazole Sandoz 10 mg tablets
Aripiprazol Sandoz 10 mg tablete
Aripiprazole Sandoz 10 mg tablets are pink coloured, mottled, round shaped tablets, with an approximate diameter of 6.0 mm, debossed with “SZ” on one side and “446” on the other side.
Aripiprazol Sandoz 10 mg tablete su ružičaste, prošarane, okrugle tablete, približnog promjera 6,0 mm, s utisnutom oznakom “SZ“ na jednoj strani i “446“ na drugoj strani.
Aripiprazole Sandoz 10 mg tablets aripiprazole
Aripiprazol Sandoz 10 mg tablete aripiprazol
Aripiprazole Sandoz 15 mg
Aripiprazol Sandoz 15 mg
Aripiprazole Sandoz 15 mg tablets are yellow coloured, mottled, round shaped tablets, with an approximate diameter of 7.0 mm, debossed with “SZ” on one side and “447” on the other side.
Aripiprazol Sandoz 15 mg tablete su žute, prošarane, okrugle tablete, približnog promjera 7,0 mm, s utisnutom oznakom “SZ“ na jednoj strani i “447“ na drugoj strani.
Aripiprazole Sandoz 15 mg tablets aripiprazole
Aripiprazol Sandoz 15 mg tablete aripiprazol
Aripiprazole Sandoz 20 mg
Aripiprazol Sandoz 20 mg
Aripiprazole Sandoz 20 mg tablets are white coloured, round shaped tablets, with an approximate diameter of 7.8 mm, debossed with “SZ” on one side and “448” on the other side.
Aripiprazol Sandoz 20 mg tablete su bijele, okrugle tablete, približnog promjera 7,8 mm, s utisnutom oznakom “SZ“ na jednoj strani i “448“ na drugoj strani.
Aripiprazole Sandoz 20 mg tablets aripiprazole
Aripiprazol Sandoz 20 mg tablete aripiprazol
Aripiprazole Sandoz 30 mg
Aripiprazol Sandoz 30 mg
Aripiprazole Sandoz 30 mg tablets
Aripiprazol Sandoz 30 mg tablete
Aripiprazole Sandoz 30 mg tablets are pink coloured, mottled, round shaped tablets, with an approximate diameter of 9.0 mm, debossed with “SZ” on one side and “449” on the other side.
Aripiprazol Sandoz 30 mg tablete su ružičaste, prošarane, okrugle tablete, približnog promjera 9,0 mm, s oznakama “SZ“ na jednoj strani i “449“ na drugoj strani.
Aripiprazole Sandoz 30 mg tablets aripiprazole
Aripiprazol Sandoz 30 mg tablete aripiprazol
Aripiprazole Sandoz 5 mg
Aripiprazol Sandoz 5 mg
Aripiprazole Sandoz 5 mg tablets aripiprazole
Aripiprazol Sandoz 5 mg tablete aripiprazol
Aripiprazole Sandoz 5 mg tablets Aripiprazole Sandoz 10 mg tablets Aripiprazole Sandoz 15 mg tablets Aripiprazole Sandoz 20 mg tablets Aripiprazole Sandoz 30 mg tablets
Aripiprazol Sandoz 5 mg tablete Aripiprazol Sandoz 10 mg tablete Aripiprazol Sandoz 15 mg tablete Aripiprazol Sandoz 20 mg tablete Aripiprazol Sandoz 30 mg tablete
Aripiprazole Sandoz 5 mg, 10 mg, 15 mg, 30 mg tablets
Aripiprazol Sandoz 5 mg, 10 mg, 15 mg, 30 mg tablete
Aripiprazole Sandoz contains the active substance aripiprazole and is a ‘generic’ and a ‘hybrid’ medicine.
Aripiprazole Sandoz sadrži djelatnu tvar aripiprazol te je "generički" i "hibridni" lijek.
Aripiprazole Sandoz is effective in a dose range of 10 to 30 mg/day.
Aripiprazol Sandoz je učinkovit u rasponu doza od 10 do 30 mg/dan.
Aripiprazole Sandoz is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment (see section 5.1).
Aripiprazol Sandoz je indiciran za liječenje umjerenih do teških maničnih epizoda u bipolarnom poremećaju tipa I te za prevenciju nove manične epizode u odraslih osoba s pretežno maničnim epizodama u kojih su prethodne manične epizode odgovorile na liječenje aripiprazolom (vidjeti dio 5.1).
Aripiprazole Sandoz is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.
Aripiprazol Sandoz je indiciran za liječenje shizofrenije u odraslih i adolescenata u dobi od 15 i više godina.
Aripiprazole Sandoz is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older (see section 5.1).
Aripiprazol Sandoz je indiciran za liječenje umjerenih do teških maničnih epizoda u bipolarnom poremećaju tipa I u adolescenata u dobi od 13 godina i starijih tijekom najdulje 12 tjedana (vidjeti dio 5.1).
Aripiprazole Sandoz is not recommended for use in patients with schizophrenia below 15 years of age due to insufficient data on safety and efficacy (see sections 4.8 and 5.1).
Aripiprazol Sandoz se ne preporučuje za primjenu u bolesnika sa shizofrenijom mlađih od 15 godina, zbog nedostatnih podataka o sigurnosti i djelotvornosti (vidjeti dijelove 4.8 i 5.1).
Aripiprazole Sandoz is used in patients aged 15 years or over; bipolar I disorder, a mental illness in which patients have manic episodes (periods of abnormally high mood), alternating with periods of normal mood.
Aripiprazole Sandoz koristi se u bolesnika u dobi od 15 godina ili starijih; kod bipolarnog poremećaja tipa I, mentalne bolesti u slučaju koje bolesnici imaju manične epizode (razdoblja abnormalno visokog raspoloženja), koje se izmjenjuju s razdobljima normalnog raspoloženja.
Aripiprazole Sandoz tablets are used to treat adults and adolescents aged 13 years and older who suffer from a condition with symptoms such as feeling "high", having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability.
Aripiprazol Sandoz tablete koriste se za liječenje odraslih osoba te adolescenata u dobi od 13 godina i starijih koji boluju od stanja čiji su simptomi “povišeno” raspoloženje, pretjerana količina energije, potreba za manjom količinom sna nego obično, vrlo brz govor i ubrzan tijek misli te ponekad teška razdražljivost.
Aripiprazole Sandoz tablets contain lactose
Aripiprazol Sandoz tablete sadrže laktozu
Aripiprazole Sandoz tablets contain lactose.
Aripiprazol Sandoz tablete sadrže laktozu.
Aripiprazole Sandoz tablets contain the active substance aripiprazole and belong to a group of medicines called antipsychotics.
Aripiprazol Sandoz tablete sadrže djelatnu tvar aripiprazol i pripadaju skupini lijekova koji se zovu antipsihotici.
Aripiprazole Sandoz tablets with food, drink and alcohol Aripiprazole Sandoz tablets can be taken regardless of meals.
Aripiprazol Sandoz tablete s hranom, pićem i alkoholom Aripiprazol Sandoz tablete mogu se uzimati neovisno o obrocima.
Aripiprazole should be used cautiously in patients at risk for aspiration pneumonia.
Aripiprazol treba primjenjivati s oprezom u bolesnika s rizikom od aspiracijske pneumonije.
Aripiprazole should be used with caution in patients with known cardiovascular disease (history of myocardial infarction or ischaemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medicinal products) or hypertension, including accelerated or malignant.
Aripiprazol treba biti primjenjivan s oprezom u bolesnika s poznatom kardiovaskularnom bolešću (infarkt miokarda ili ishemijska bolest srca, zatajenje srca ili poremećaji provođenja u povijesti bolesti), cerebrovaskularnom bolešću, stanjima zbog kojih su bolesnici skloni hipotenziji (dehidracija, hipovolemija i liječenje antihipertenzivnim lijekovima) ili hipertenziji, uključujući ubrzanu ili malignu hipertenziju.
Aripiprazole was studied in a 30-week placebo-controlled trial involving 296 children and adolescents (10- 17 years), who met DSM-IV criteria for Bipolar I Disorder with manic or mixed episodes with or without psychotic features and had a Y-MRS score ≥ 20 at baseline.
Aripiprazol se ispitivao u 30-tjednom placebom kontroliranom ispitivanju u kojem je sudjelovalo 296 djece i adolescenata (10-17 godina) koji su zadovoljavali DSM-IV kriterije za bipolarni poremećaj tipa I s maničnim ili miješanim epizodama, s psihotičnim značajkama ili bez njih, i koji su na početku liječenja imali Y-MRS rezultat ≥ 20.
Aripiprazole was studied in a 30-week placebo-controlled trial involving 296 children and adolescents (10-17 years), who met DSM-IV criteria for Bipolar I Disorder with manic or mixed episodes with or without psychotic features and had a Y-MRS score ≥ 20 at baseline.
Aripiprazol se ispitivao u 30-tjednom placebom kontroliranom ispitivanju u kojem je sudjelovalo 296 djece i adolescenata (10-17 godina) koji su zadovoljavali DSM-IV kriterije za bipolarni poremećaj tipa I s maničnim ili miješanim epizodama, s psihotičnim značajkama ili bez njih, i koji su na početku liječenja imali Y-MRS rezultat ≥ 20.
Aripiprazole Zentiva contains the active substance aripiprazole and is a ‘generic medicine’.
Aripiprazole Zentiva sadrži djelatnu tvar aripiprazol i "generički je lijek".
Aripiprazole Zentiva is available as tablets (5, 10, 15 and 30 mg) and orodispersible tablets (tablets that dissolve in the mouth; 10, 15 and 30 mg).
Aripiprazole Zentiva je dostupan kao tablete od (5, 10, 15 i 30 mg) i orodisperzivne tablete (tablete koje se otapaju u ustima; 10, 15 i 30 mg).
Aripiprazole Zentiva is used in patients aged 15 years or over; bipolar I disorder, a mental illness in which patients have manic episodes (periods of abnormally high mood), alternating with periods of normal mood.
Aripiprazole Zentiva se koristi u bolesnika u dobi od 15 godina ili starijih; bipolarnom poremećaju tipa I, mentalnom bolesti u slučaju koje bolesnici imaju manične epizode (razdoblja abnormalno visokog raspoloženja), koje se izmjenjuju s razdobljima normalnog raspoloženja.
Arixtra 1.5 mg/0.3 ml injection fondaparinux Na
Arixtra 1,5 mg/0,3 ml otopina za injekciju fondaparinuks Na
Arixtra 1.5 mg/0.3 ml solution for injection fondaparinux sodium
Arixtra 1,5 mg/0,3 ml otopina za injekciju fondaparinuksnatrij
Arixtra 10 mg/0.8 ml injection fondaparinux Na
Arixtra 10 mg/0,8 ml otopina za injekciju fondaparinuks Na
Arixtra 10 mg/0.8 ml solution for injection fondaparinux sodium
Arixtra 10 mg/0,8 ml otopina za injekciju fondaparinuksnatrij
Arixtra 2.5 mg/0.5 ml injection fondaparinux Na
Arixtra 2,5 mg/0,5 ml otopina za injekciju fondaparinuks Na
Arixtra 2.5 mg/0.5 ml solution for injection fondaparinux sodium
Arixtra 2,5 mg/0,5 ml otopina za injekciju fondaparinuksnatrij
Arixtra 5 mg/0.4 ml injection fondaparinux Na
Arixtra 5 mg/0,4 ml otopina za injekciju fondaparinuks Na
Arixtra 5 mg/0.4 ml solution for injection fondaparinux sodium
Arixtra 5 mg/0,4 ml otopina za injekciju fondaparinuksnatrij
Arixtra 7.5 mg/0.6 ml injection fondaparinux Na
Arixtra 7,5 mg/0,6 ml otopina za injekciju fondaparinuks Na
Arixtra 7.5 mg/0.6 ml solution for injection fondaparinux sodium
Arixtra 7,5 mg/0,6 ml otopina za injekciju fondaparinuksnatrij
Arixtra contains a synthetic substance called fondaparinux sodium.
Arixtra sadržava fondaparinuksnatrij, sintetički spoj koji ometa djelovanje faktora zgrušavanja Xa
Arixtra does not contain any animal products.
Arixtra ne sadržava sastojke životinjskog porijekla.